Blood pressure lowering effect of statin drugs with an application to rosuvastatin

Young-A Heo; Mijeong Son; Kyungsoo Park

doi:10.12793/tcp.2016.24.3.132

Journal List > Transl Clin Pharmacol > v.24(3) > 1082624

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Heo, Son, and Park: Blood pressure lowering effect of statin drugs with an application to rosuvastatin

Original Article

Translational and Clinical Pharmacology 2016;24(3):132-136.

Published online: 19 January 2016

DOI: https://doi.org/10.12793/tcp.2016.24.3.132

Blood pressure lowering effect of statin drugs with an application to rosuvastatin

Young-A Heo^1,², Mijeong Son^1,², Kyungsoo Park^∗,¹

¹Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Korea

²Brain Korea 21 Plus Project for Medical Science, Yonsei University, Seoul 03722, Korea

^∗Correspondence: K. S. Park; Tel: +82-2-2228-1735, Fax: +82-2-313-1894, E-mail: kspark@yuhs.ac

Received 24 July 2016 Revised 2 September 2016 Accepted 2 September 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hyperlipidemia and hypertension are among the major risk factors for cardiovascular disease (CVD) and they often co-exist within a single patient. Recently, many studies published results regarding the potential role of statins in decreasing blood pressure (BP) however there is still a controversy over the efficacy of statin therapy on BP. This study aimed to investigate the potential role of rosuvastatin in BP lowering properties in Korean population. Data were taken from three randomized, multiple-dose cross over studies for rosuvastatin, angiotensin II receptor blocker (ARB) and metformin monotherapies and the combined therapy of rosuvastatin and ARB, in total of 91 healthy male normotensive subjects. Measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP) at the baseline before treatment begins and for 24 hours after the last dose were used in the analysis. The analysis variables used were (i) the mean change in steady-state BP from the baseline, symbolized as ΔBP, and (ii) the difference in ΔBP between the ARB monotherapy and the combined therapy, symbolized as ΔBP,d. The ^△BP and ΔBP,d for SBP from each study varied in -0.1 ~ -1.3 mmHg and 1.2 ~ 1.6 mmHg, respectively, and were not significantly different from zero. The ^△BP and ΔBP,d for DBP from each study varied in -2.8 ~ -1.4 mmHg and -2.9 ~ -1.8, respectively, which were statistically significant for ^△BP (p < 0.05) but was not for ΔBP,d (p > 0.05). These results indicated that the rosuvastatin monotherapy may produce small blood pressure lowing effect in DBP.

Keywords: rosuvastatin, systolic blood pressure, diastolic blood pressure, normotensive

REFERENCES

1.Jang JY., Lee SH., Kim BS., Seo HS., Kim WS., Ahn Y, et al. Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circ J. 2015. 45:225–233. DOI: doi: 10.4070/kcj.2015.45.3.225.

2.Banach M., Nikfar S., Rahimi R., Bielecka-Dabrowa A., Pencina MJ., Mikhailidis DP, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects—a meta-analysis of randomized controlled trials. Int J Cardiol. 2013. 168:2816–2824. DOI: doi: 10.1016/j.ijcard.2013.03.068.

3.Borghi C., Prandin M., Costa F., Bacchelli S., Degli Esposti D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000. 35:549–555.

4.Briasoulis A., Agarwal V., Valachis A., Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich). 2013. 15:310–320. DOI: doi: 10.1111/jch.12081.

5.Golomb BA., Dimsdale JE., White HL., Ritchie JB., Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008. 168:721–727. DOI: doi: 10.1001/archinte.168. 7.721.

6.Aydin U., Ugurlucan M., Gungor F., Ziyade S., Inan B., Banach M, et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology. 2009. 60:370–377. DOI: doi: 10.1177/0003319708321102.

7.John S., Schneider MP., Delles C., Jacobi J., Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005. 149:473.

8.Katsiki N., Mikhailidis DP., Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens. 2011. 29:2493–2494. author reply 4.DOI: doi: 10.1097/HJH.0b013e32834c7bc9.

9.Stepien M., Banach M., Mikhailidis DP., Gluba A., Kjeldsen SE., Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin. 2009. 25:1995–2005. DOI: doi: 10.1185/03007990903098081.

10.Osende JI., Ruiz-Ortega M., Blanco-Colio LM., Egido J. Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrol Dial Transplant. 2004. 19:528–531.

11.Strazzullo P., Kerry SM., Barbato A., Versiero M., D'Elia L., Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007. 49:792–798.

12.Lee D., Roh H., Son H., Jang SB., Lee S., Nam SY, et al. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Clin Ther. 2014. 36:1171–1181. DOI: doi: 10.1016/j.clinthera.2014.06.004.

13.Roh H., Son H., Lee D., Chang H., Yun C., Park K. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clin Ther. 2014. 36:1159–1170. DOI: doi: 10.1016/j.clinthera.2014.06.022.

14.Son M., Kim Y., Lee D., Roh H., Son H., Guk J, et al. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. Clin Ther. 2014. 36:1147–1158. DOI: doi: 10.1016/j.clinthera.2014.06.007.

15.Wassmann S., Laufs U., Bäumer AT., Müller K., Ahlbory K., Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001. 37:1450–1457.

16.Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002. 942:23–30.

Figure 1.

Mean (SD) BP profile at baseline and for 24 hours after the last dose for SBP (a) and DBP (b) for rosuvastatin monotherapy

Figure 2.

Mean (SD) BP profile at baseline and for 24 hours after the last dose for SBP (a) and DBP (b) for combination therapy of rosuvastatin and olmesartan (upper) and rosuvastatin and telmisartan (lower)

Table 1.

Characteristics of clinical trials included in the analysis

Study, Design	Subjects (no. of subjects)	Dosage per day	Duration of study	BP sampling Schedule
Randomized, open-label, 3-period, multiple-dose crossover study[13]	Healthy normotensive male subjects[35]	20 mg	7 days	At predose on days 1 through 6 and at 0, 2, 4, 8, 12, 24, 48 and 72 hours after the last dose on day 7
Randomized, open-label, 2-part, 2-period, multiple-dose crossover study[14]	Healthy normotensive male subjects[23]	20 mg	6 days	At predose on days 1 through 5 and at 0, 2, 4, 8, 12, 24, 48 and 72 hours after the last dose on day 6
Randomized, open-label, 6-sequence, 3-period, multiple-dose crossover study[12]	Healthy normotensive male subjects[33]	10 mg	5 days	At predose on days 1 through 4 and at 0, 4, 8, 12, 24, 48 and 72 hours after the last dose on day 5

Table 2.

T-test results for rosuvastatin monotherapy

	△BP for SBP (mmHg)			△BP for DBP (mmHg)
	μ	CI	p-value	μ	CI	p-value
Lee et al[12]	-0.1	-3.4 ~ 3.3	0.4867	-1.8	-3.3 ~ -0.3	0.0269
Roh et al[13]	-1.3	-3.7 ~ 1.2	0.1910	-1.4	-2.5 ~ -0.3	0.0219
Son et al[14]	-0.1	-2.4 ~ 2.2	0.4786	-2.8	-4.9 ~ -0.7	0.0165

Table 3.

T-test results for combination therapy of rosuvastatin and olmesartan (Roh et al) or telmisartan (Son et al)

	△BP,d for SBP (mmHg)			△BP,d for DBP (mmHg)
	μ	CI	p-value	μ	CI	p-value
Roh et al[13]	1.2	-3.2 ~ 5.6	0.6799	-2.9	-6.1 ~ 0.3	0.0655
Son et al[14]	1.6	-4.9 ~ 7.4	0.4623	-1.8	-7.3 ~ 3.7	0.2868

TOOLS

Similar articles